Ten piglets (weight range: 5.2 to 6.5 kg) were experimentally infected with E.coli K88. They were divided into two groups: One received Baytril® 2.5% injectable solution i.m. (2.5 mg/kg bw on three consecutive days); the other group served as untreated control. Baytril® treatment was effective. (Bauditz, G, 1985. Therapeutischer Wirksamkeit bei experimentäler Infektion von Absatzferkeln mit E coli. internal report 10296. Bayer Animal Health GmbH, Monheim, Germany)

Trial 1:

Mortality

 

Ten animals were infected with E. coli K88:

Mortality

In another trial, 30 pigs (weight range: 7.3 to 19.4 kg) were divided into three groups of ten animals each and infected with E.coli O147. Severe diarrhea was noticed eight hours after infection. One group received Baytril® 2.5% injectable solution i.m. (2.5 mg/kg bw on three consecutive days); the second group was treated the same way but with a dosage of 1 mg/kg bw. The third group served as controls.
Whilst in the treated groups all animals survived, the mortality of the controls raised to 80% on the eighth day after infection. The number of the pathogenic E.coli that could be isolated per gram feces dropped remarkably in the treated groups and ended after day three.
(Bauditz, G, 1985. Therapeutischer Wirksamkeit bei experimentäler Infektion von Absatzferkeln mit E coli. internal report 10296. Bayer Animal Health GmbH, Monheim, Germany)

Trial 2:

Reduction of Colony-Forming Units


Reduction of Colony-Forming Units

The efficacy was also tested in an outbreak ofE.coli diarrhoea in suckling piglets. Baytril® was tested in dose rates of 1.25, 2.5 and 5 mg/kg bw (given as 2.5 % injectable solution applied i.m.).
The treatment success was compared with the efficacy of oxytetracycline, given at a dose rate of 10 mg/kg bw in the form of 5% injectable solution i.m.. The overall clinical efficacy was 61% for oxytetracycline, and 89%, 96% and 94% for the groups treated with 1.25, 2.5 and 5 mg/kg bw of Baytril® respectively.

Trial 3:

Clinical cure in newborn colibacillosis

Clinical cure in newborn colibacillosis